Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 14/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593208 | 0.94 | FGFR4 (0.48) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL13593199 | 0.87 | FGFR4 (0.50) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL3971306 | 0.85 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL13593204 | 0.84 | FGFR4 (0.51) | FGFR4FGFR1FGFR2FGFR3TNK2 | |
| SCHEMBL13593195 | 0.78 | FGFR4 (0.62) | FGFR4FGFR1FGFR2FGFR3TNK2 | |
| SCHEMBL3976966 | 0.78 | CDK1 (0.53) | FGFR4FGFR1FGFR2FGFR3BRD4 | |
| SCHEMBL3976088 | 0.78 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL13593194 | 0.77 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3TNK2 | |
| SCHEMBL3970204 | 0.77 | FGFR4 (0.59) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL17857067 | 0.77 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| WO-2007136465-A2 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312321-A1 | COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS | PTK2B, SGK2, FRK | FGFR4 200/4885FGFR1 92/4885FGFR2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.